Orphazyme ApS (Copenhagen, Denmark) develops new therapies for the treatment of rare and genetic diseases.
The company was founded on pioneering research from the laboratory of Professor Marja Jäättela, with the aim of converting human chaperone proteins into effective therapies for degenerative diseases. Orphazyme's novel technology also has the potential to address the neurodegenerative aspects of these devastating diseases.
Orphazyme’s core program is developing heat shock protein based therapies for the treatment of diseases caused by defects in the function and/or metabolism of proteins. The company focuses on severe and often fatal diseases with a very high unmet need.Continue reading Read our latest research article in Science Translational Medicine